S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Chevron Delights Shareholders with $75 Billion in Share Buybacks
Mergers and Acquisitions in 2023 Off To A Strong Start
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Chevron Delights Shareholders with $75 Billion in Share Buybacks
Mergers and Acquisitions in 2023 Off To A Strong Start
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Chevron Delights Shareholders with $75 Billion in Share Buybacks
Mergers and Acquisitions in 2023 Off To A Strong Start
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Chevron Delights Shareholders with $75 Billion in Share Buybacks
Mergers and Acquisitions in 2023 Off To A Strong Start
NASDAQ:EVFM

Evofem Biosciences - EVFM Stock Forecast, Price & News

$0.05
0.00 (0.00%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.05
$0.06
50-Day Range
$0.05
$0.08
52-Week Range
$0.05
$8.04
Volume
1.76 million shs
Average Volume
2.04 million shs
Market Capitalization
$7.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.35

Evofem Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
9,807.4% Upside
$5.35 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.93) to ($0.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars


EVFM stock logo

About Evofem Biosciences (NASDAQ:EVFM) Stock

Evofem Biosciences, Inc., is a small biopharmaceutical company with a single commercial product as well as a pipeline of potential winners. The company works to develop and commercialize a variety of product lines intended to address unmet needs in women’s sexual and reproductive health. The company’s motto is Science With A Soul and its aim is to improve women’s lives with innovative solutions. In fact, the sole purpose of the company is to improve the quality of women’s lives by enabling greater control of their healthcare needs.

Evofem Biosciences went public in January 2018. The company is headquartered in San Diego, California, and is led by Saundra Pelletier. Ms. Pelletier has been CEO, president, and executive director of the company since February 2015 and is instrumental in the company’s transition to a publicly traded issue. Ms. Pelletier has more than 25 years of experience in the pharmaceutical industry and is responsible for launching and expanding the use of many brands.

Evofem’s primary commercial product is Phexxi. Phexxi is a vaginal gel for the prevention of pregnancy. Phexxi is the US first and only hormone-free prescription birth control product that is controlled by the individual. It stands out from other methods because it is hormone free, requires no daily usage, comes with no invasive procedures, and is easy to carry in a bag and use when needed.

Phexxi works by maintaining vaginal pH after intercourse and relies on 3 naturally occurring chemicals that are regularly found in food: lactic acid, citric acid, and potassium bitartrate (cream of tartar for the chefs out there). The product works because sperm need a higher pH to thrive than what is normal in women’s health and that is provided by the semen. Phexxi’s acidic composition is formulated to maintain the ideal pH and keep the sperm inactive. Phexxi can also block the cervical opening and prevent sperm from entering.

Among the many advantages of Phexxi are reduced or non-existent side effects as compared to other forms of birth control which include mood swings, headaches, and irritability. The product is approved by the FDA and prescriptions can be filled via telehealth appointment. The company estimates each 100 basis points of US market share it can secure is worth $300 million in annual revenue.

The opportunity for Evofem is that its product, Phexxi, has been shown to be effective in fighting the transmission of gonorrhea and chlamydia. The transmission of both STDs has been associated with higher pH levels which Phexxi is specifically fighting. The investigational drug EV-100 (Phexxi) has made it through to Phase 3 clinical testing and regulatory filings are expected. The company also has two other products in development and they are on track to enter clinical trials.

 

Receive EVFM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evofem Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVFM Stock News Headlines

Costco Adds Phexxi® to Member Prescription Program
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Evofem Biosciences
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Evofem Biosciences Announces Uplisting to OTCQB
Inventor of the Year Awarded to Developer of Phexxi®
Evofem Obtains Forbearance From Debtholders For Existing Matters
Evofem Announces Successful Debt Restructuring
4 Analysts Have This to Say About Evofem Biosciences
Evofem Biosciences Strengthens Board of Directors
See More Headlines
Receive EVFM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evofem Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVFM Company Calendar

Last Earnings
11/15/2021
Today
1/27/2023
Next Earnings (Estimated)
3/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVFM
Employees
119
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.35
High Stock Price Forecast
$8.55
Low Stock Price Forecast
$3.50
Forecasted Upside/Downside
+9,807.4%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-205,190,000.00
Net Margins
-592.88%
Pretax Margin
-592.67%

Debt

Sales & Book Value

Annual Sales
$8.24 million
Book Value
($9.59) per share

Miscellaneous

Free Float
135,115,000
Market Cap
$7.59 million
Optionable
Not Optionable
Beta
-1.27

Key Executives

  • Saundra L. PelletierSaundra L. Pelletier
    Chairman, President & Chief Executive Officer
  • Justin J. FileJustin J. File
    Chief Financial Officer & Secretary
  • Brandi Howard
    Head-Medical Affairs
  • Bret Henning
    Senior Director-Information Technology
  • Jessie Degarmo
    Office Administrator













EVFM Stock - Frequently Asked Questions

Should I buy or sell Evofem Biosciences stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EVFM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVFM, but not buy additional shares or sell existing shares.
View EVFM analyst ratings
or view top-rated stocks.

What is Evofem Biosciences' stock price forecast for 2023?

4 Wall Street research analysts have issued twelve-month target prices for Evofem Biosciences' shares. Their EVFM share price forecasts range from $3.50 to $8.55. On average, they expect the company's stock price to reach $5.35 in the next year. This suggests a possible upside of 9,807.4% from the stock's current price.
View analysts price targets for EVFM
or view top-rated stocks among Wall Street analysts.

How have EVFM shares performed in 2023?

Evofem Biosciences' stock was trading at $0.0640 on January 1st, 2023. Since then, EVFM shares have decreased by 15.6% and is now trading at $0.0540.
View the best growth stocks for 2023 here
.

When is Evofem Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our EVFM earnings forecast
.

How were Evofem Biosciences' earnings last quarter?

Evofem Biosciences, Inc. (NASDAQ:EVFM) issued its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($7.20) earnings per share for the quarter, missing analysts' consensus estimates of ($4.50) by $2.70. The biotechnology company had revenue of $1.71 million for the quarter, compared to analyst estimates of $3.39 million. During the same period last year, the company earned ($4.95) earnings per share.

When did Evofem Biosciences' stock split?

Evofem Biosciences's stock reverse split before market open on Friday, May 6th 2022. The 1-15 reverse split was announced on Friday, May 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Evofem Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evofem Biosciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Organigram (OGI), Gran Tierra Energy (GTE), Novan (NOVN) and KushCo (KSHB).

What is Evofem Biosciences' stock symbol?

Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."

How do I buy shares of Evofem Biosciences?

Shares of EVFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evofem Biosciences' stock price today?

One share of EVFM stock can currently be purchased for approximately $0.05.

How much money does Evofem Biosciences make?

Evofem Biosciences (NASDAQ:EVFM) has a market capitalization of $7.59 million and generates $8.24 million in revenue each year. The biotechnology company earns $-205,190,000.00 in net income (profit) each year or ($19.5939) on an earnings per share basis.

How many employees does Evofem Biosciences have?

The company employs 119 workers across the globe.

How can I contact Evofem Biosciences?

Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The official website for the company is www.evofem.com. The biotechnology company can be reached via phone at (858) 550-1900, via email at araskopf@evofem.com, or via fax at 844-828-2010.

This page (NASDAQ:EVFM) was last updated on 1/27/2023 by MarketBeat.com Staff